Cited in boardrooms, legal proceedings & government briefings since 2017

Prohibition Partners estimates that, in 2022, the global sales of CBD, medical and adult-use cannabis amounted to US$45 billion and could be worth more than US$101 billion by 2026.
Cited in boardrooms, legal proceedings & government briefings since 2017. Our figures are built to be defended — sourced, modelled and signed off by PP’s analysts.
Trusted by teams at
Prohibition Partners estimates that, in 2022, the global sales of CBD, medical and adult-use cannabis amounted to US$45 billion and could be worth more than US$101 billion by 2026. It combines PP’s proprietary market sizing with regulatory analysis, giving investors and corporates a single, citable reference — delivered digitally, licensed for internal use, and backed by the analysts who built the numbers.
PDF + data
delivery format
2021
published
Prohibition Partners estimates that, in 2022, the global sales of CBD, medical and adult-use cannabis amounted to US$45 billion and could be worth more than US$101 billion by 2026. Cannabis liberalisation is accelerating, with an increasing number of States and countries legalising cannabis for adult-use and medical purposes The financial climate for cannabis operators remains tough, as impacts from the COVID pandemic and Russia-Ukraine war slow the flow of capital to the industry
Investors & analysts
Defensible sizing and forecasts to underwrite the thesis.
Corporate strategy & FMCG
Opportunity sizing and entry routes across key markets.